Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3)

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Yamamoto, Kazuhiro ^a   Mizumoto, Atsushi ^b   Nishimura, Kohji ^b   Uda, Atsushi ^a   Mukai, Akira ^a   Yamashita, Kazuhiko ^a   Kume, Manabu ^a   Makimoto, Hiroo ^a   Bito, Toshinori ^b   Nishigori, Chikako ^b   Nakagawa, Tsutomu ^a,b   Hirano, Takeshi ^a,b   Hirai, Midori ^a,b  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN MCL 1; SERINE; SORAFENIB; STAT3 PROTEIN; STAT3C PROTEIN; STATTIC; SUNITINIB; SURVIVIN; TYROSINE; UNCLASSIFIED DRUG; 2-(2-METHOXY-4-NITROPHENYL)-3-(4-NITROPHENYL)-5-(2,4-DISULFOPHENYL)-2H TETRAZOLIUM MONOSODIUM SALT; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; STAT3 PROTEIN, HUMAN; SULFOXIDE; TETRAZOLIUM;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; KERATINOCYTE; LONG TERM CARE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; WST ASSAY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TOXICITY; TRANSFORMED CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CYCLIC S-OXIDES; GENE EXPRESSION REGULATION; HUMANS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; KERATINOCYTES; MITOGEN-ACTIVATED PROTEIN KINASES; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TETRAZOLIUM SALTS;

EID: 84904265353     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102110     Document Type: Article

References (39)

1. Calvo E, Ravaud A, Bellmunt J (2013) What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev 39: 366-374.
2. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, et al. (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326-334. (Pubitemid 43338212)
3. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109. (Pubitemid 39331023)
4. Larkin J, Paine A, Tumur I, Cappelleri JC, Healey PJ, Sr., et al. (2013) Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert Opin Pharmacother 14: 27-39.
5. Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, et al. (2012) Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 61: 307-316.
6. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, et al. (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161: 1045-1051.
7. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856. (Pubitemid 350224094)
8. Yu H, Jove R (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105. (Pubitemid 38198738)
9. Darnell Jr JE (1997) STATs and Gene Regulation. Science 277: 1630-1635.
10. Levy DE, Darnell JE, Jr. (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662. (Pubitemid 34987786)
11. Sen N, Che X, Rajamani J, Zerboni L, Sung P, et al. (2012) Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicellazoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A 109: 600-605.
12. Aoki Y, Feldman GM, Tosato G (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535-1542. (Pubitemid 36182531)
13. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, et al. (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362.
14. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, et al. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618. (Pubitemid 35398808)
15. Quadros MR, Peruzzi F, Kari C, Rodeck U (2004) Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res 64: 3934-3939. (Pubitemid 38697307)
16. Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13: 1235-1242. (Pubitemid 44750735)
17. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771. (Pubitemid 18089976)
18. Yamamoto K, Uda A, Mukai A, Yamashita K, Kume M, et al. (2013) Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition. J Exp Clin Cancer Res 32: 83.
19. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. (1999) Stat3 as an oncogene. Cell 98: 295-303. (Pubitemid 29380565)
20. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, et al. (2005) Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11: 43-49. (Pubitemid 40215836)
21. Fournier C, Tisman G (2010) Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J 16: 17.
22. Degen A, Alter M, Schenck F, Satzger I, Volker B, et al. (2010) The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 8: 652-661.
23. McLellan B, Kerr H (2011) Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther 24: 396-400.
24. Yang CH, Chuang CK, Hsieh JJ, Chang JW (2010) Targeted therapy and handfoot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf 9: 459-470.
25. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, et al. (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69: 2506-2513.
26. Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, et al. (2012) Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer 130: 2693-2702.
27. Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, et al. (2012) Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 23: 3137-3143.
28. Stephanou A, Brar BK, Knight RA, Latchman DS (2000) Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7: 329-330. (Pubitemid 30192982)
29. Marconi A, Dallaglio K, Lotti R, Vaschieri C, Truzzi F, et al. (2007) Survivin identifies keratinocyte stem cells and is downregulated by anti-beta1 integrin during anoikis. Stem Cells 25: 149-155. (Pubitemid 46052985)
30. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, et al. (2002) Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115: 575-585. (Pubitemid 34182984)
31. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, et al. (1999) Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 19: 7519-7528. (Pubitemid 29493415)
32. Tarutani M, Nakajima K, Takaishi M, Ohko K, Sano S (2013) Epidermal hyperplasia induced by Raf-MAPK signaling requires Stat3 activation. J Dermatol Sci 72: 110-115.
33. Carlo-Stella C, Locatelli SL, Giacomini A, Cleris L, Saba E, et al. (2013) Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. PLoS One 8: e61603.
34. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, et al. (2010) PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 30: 4951-4958.
35. Coriat R, Nicco C, Chereau C, Mir O, Alexandre J, et al. (2012) Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 11: 2284-2293.
36. Rainer PP, Doleschal B, Kirk JA, Sivakumaran V, Saad Z, et al. (2012) Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes. BJU Int 110: 1455-1462.
37. Park GB, Choi Y, Kim YS, Lee HK, Kim D, et al. (2014) ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells. Int J Oncol 44: 977-985.
38. Iijima M, Fukino K, Adachi M, Tsukamoto T, Murai M, et al. (2011) Sorafenib-associated hand-foot syndrome in Japanese patients. J Dermatol 38: 261-266.
39. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, et al. (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13: 1001-1011.